Rznomics' RNA-editing cancer therapy RZ-001 recommended for EU orphan drug designation in glioma
What's the news? Rznomics, a South Korean developer of RNA-based medicines, said on 28 September ️2026 that the European Medicines Agency's Committee for Orphan Medicinal Products has recommended its lead cancer therapy, RZ-001, for orphan drug designation to treat glioma — a type of brain tumour that starts in the supportive tissue around nerve cells. The recommendation was based on clinical responses seen in patients with recurrent glioblastoma, the most aggressive form of brain cancer, including sustained disappearance of tumours on imaging scans in several patients;it now goes to the European Commission for a final decision.
How it works: RZ-001, also known as taspitimagene advec, is an RNA-editing gene therapy: rather than altering DNA permanently, it corrects disease-related RNA messages using the body's own machinery, temporarily restoring normal protein production. It is designed to target tumours carrying an enzyme called telomerase, which helps cancer cells divide without limit, and is being studied in patients whose tumours test positive for this marker. RZ-001 is currently in early-stage clinical trials (Phase ️1/2a) in South Korea and the United States for patients with recurrent glioblastoma.
Why it matters: An orphan drug designation is reserved for medicines aimed at rare diseases that affect fewer than five in ️10,000 people in Europe. It comes with practical benefits — protocol assistance from the EMA on trial design and regulatory strategy, fee reductions, and, if RZ-001 is eventually approved for glioma, up to ️10 years of market exclusivity in the EU, shielding it from direct competition. The news builds on an earlier regulatory endorsement:in May ️2026 the U.S. Food and Drug Administration granted RZ-001 a regenerative medicine advanced therapy (RMAT) designation for hepatocellular carcinoma, the most common form of liver cancer, underscoring the company's ambition to broaden the therapy beyond brain cancer.
Read more: Seoul Economic Daily, 28 September ️2026 · The Asia Business Daily, 28 September ️2026
